Tmsbl1 inhibitors are a class of chemical compounds that specifically target the Tmsbl1 protein, which is involved in cellular and molecular processes critical to maintaining biological functions. These inhibitors typically function by binding to the active site of the Tmsbl1 protein, blocking the interaction between the protein and its natural substrates or cofactors. By occupying the active site, Tmsbl1 inhibitors prevent the protein from carrying out its usual biochemical reactions, effectively halting its biological activity. Some Tmsbl1 inhibitors may also exert their effects by binding to allosteric sites, regions distinct from the active site, causing conformational changes in the protein that lead to a reduction or complete inhibition of its function. The binding of these inhibitors is stabilized by non-covalent forces, such as hydrogen bonding, van der Waals interactions, hydrophobic contacts, and electrostatic forces, which ensure that the inhibitors remain tightly associated with the Tmsbl1 protein, blocking its activity efficiently.
The structural diversity of Tmsbl1 inhibitors is key to their functionality, allowing for precise interactions with various regions of the Tmsbl1 protein. These inhibitors often incorporate functional groups such as hydroxyl, amine, or carboxyl groups that facilitate specific interactions with the protein's amino acid residues, particularly in the binding pocket. Aromatic rings and heterocyclic structures are also commonly included in the design of Tmsbl1 inhibitors, as they enhance hydrophobic interactions with non-polar regions of the protein and contribute to the overall stability of the inhibitor-protein complex. The physicochemical properties of Tmsbl1 inhibitors, including molecular weight, solubility, polarity, and lipophilicity, are carefully optimized to ensure effective binding and stability in various biological environments. By balancing hydrophilic and hydrophobic regions within their molecular structure, Tmsbl1 inhibitors can efficiently interact with both polar and non-polar regions of the protein, ensuring selective and robust inhibition across a range of conditions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A potent inhibitor of ROCK (Rho-associated protein kinase), which is involved in cell migration and could influence Tβ15a-mediated cellular processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
Inhibits TGF-β receptor type I, potentially affecting Tβ15a expression levels as TGF-β signaling can regulate various aspects of tumor metastasis and growth. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that could alter cell migration and survival pathways, indirectly affecting Tβ15a activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibits MEK1/2, part of the MAPK/ERK pathway, which may regulate Tβ15a expression or function in cell migration and angiogenesis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor, potentially reducing Tβ15a activity by altering signaling pathways involved in cell motility and angiogenesis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, affecting cell migration and survival, pathways in which Tβ15a could be involved. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent PI3K inhibitor, potentially affecting pathways related to Tβ15a activity in cell migration and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which could influence Tβ15a expression and its role in cell migration and angiogenesis. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A Src kinase inhibitor, potentially affecting Tβ15a activity by modulating cell migration and invasion processes. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Targets EGFR tyrosine kinase, possibly affecting Tβ15a activity indirectly by influencing cell migration and proliferation pathways. | ||||||